219 related articles for article (PubMed ID: 34526551)
1. Functionally diverse heteromeric traps for ligands of the transforming growth factor-β superfamily.
Kumar R; Grinberg AV; Li H; Kuo TH; Sako D; Krishnan L; Liharska K; Li J; Grenha R; Maguire MC; Briscoe SD; Pearsall RS; Herrin BR; Suragani RNVS; Castonguay R
Sci Rep; 2021 Sep; 11(1):18341. PubMed ID: 34526551
[TBL] [Abstract][Full Text] [Related]
2. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer.
Tsuchida K; Nakatani M; Uezumi A; Murakami T; Cui X
Endocr J; 2008 Mar; 55(1):11-21. PubMed ID: 17878607
[TBL] [Abstract][Full Text] [Related]
3. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders.
Li J; Fredericks M; Cannell M; Wang K; Sako D; Maguire MC; Grenha R; Liharska K; Krishnan L; Bloom T; Belcheva EP; Martinez PA; Castonguay R; Keates S; Alexander MJ; Choi H; Grinberg AV; Pearsall RS; Oh P; Kumar R; Suragani RN
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586684
[TBL] [Abstract][Full Text] [Related]
4. Activin E is a transforming growth factor β ligand that signals specifically through activin receptor-like kinase 7.
Vestal KA; Kattamuri C; Koyiloth M; Ongaro L; Howard JA; Deaton AM; Ticau S; Dubey A; Bernard DJ; Thompson TB
Biochem J; 2024 Apr; 481(7):547-564. PubMed ID: 38533769
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor.
Persson U; Souchelnytskyi S; Franzén P; Miyazono K; ten Dijke P; Heldin CH
J Biol Chem; 1997 Aug; 272(34):21187-94. PubMed ID: 9261125
[TBL] [Abstract][Full Text] [Related]
6. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
Mazerbourg S; Klein C; Roh J; Kaivo-Oja N; Mottershead DG; Korchynskyi O; Ritvos O; Hsueh AJ
Mol Endocrinol; 2004 Mar; 18(3):653-65. PubMed ID: 14684852
[TBL] [Abstract][Full Text] [Related]
7. Receptor oligomerization and beyond: a case study in bone morphogenetic proteins.
Heinecke K; Seher A; Schmitz W; Mueller TD; Sebald W; Nickel J
BMC Biol; 2009 Sep; 7():59. PubMed ID: 19735544
[TBL] [Abstract][Full Text] [Related]
8. ALK4 functions as a receptor for multiple TGF beta-related ligands to regulate left-right axis determination and mesoderm induction in Xenopus.
Chen Y; Mironova E; Whitaker LL; Edwards L; Yost HJ; Ramsdell AF
Dev Biol; 2004 Apr; 268(2):280-94. PubMed ID: 15063168
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor-resistant type I receptors reveal specific requirements for TGF-beta signaling in vivo.
Ho DM; Chan J; Bayliss P; Whitman M
Dev Biol; 2006 Jul; 295(2):730-42. PubMed ID: 16684517
[TBL] [Abstract][Full Text] [Related]
10. Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal.
Kelber JA; Shani G; Booker EC; Vale WW; Gray PC
J Biol Chem; 2008 Feb; 283(8):4490-500. PubMed ID: 18089557
[TBL] [Abstract][Full Text] [Related]
11. Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1.
Lux A; Attisano L; Marchuk DA
J Biol Chem; 1999 Apr; 274(15):9984-92. PubMed ID: 10187774
[TBL] [Abstract][Full Text] [Related]
12. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily.
Barbara NP; Wrana JL; Letarte M
J Biol Chem; 1999 Jan; 274(2):584-94. PubMed ID: 9872992
[TBL] [Abstract][Full Text] [Related]
13. Engineering and therapeutic application of single-chain bivalent TGF-β family traps.
Zwaagstra JC; Sulea T; Baardsnes J; Lenferink AE; Collins C; Cantin C; Paul-Roc B; Grothe S; Hossain S; Richer LP; L'Abbé D; Tom R; Cass B; Durocher Y; O'Connor-McCourt MD
Mol Cancer Ther; 2012 Jul; 11(7):1477-87. PubMed ID: 22562986
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral gene transfer allows Smad-responsive gene promoter analyses and delineation of type I receptor usage of transforming growth factor-beta family ligands in cultured human granulosa luteal cells.
Kaivo-Oja N; Mottershead DG; Mazerbourg S; Myllymaa S; Duprat S; Gilchrist RB; Groome NP; Hsueh AJ; Ritvos O
J Clin Endocrinol Metab; 2005 Jan; 90(1):271-8. PubMed ID: 15483083
[TBL] [Abstract][Full Text] [Related]
15. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors.
Harrison CA; Gray PC; Fischer WH; Donaldson C; Choe S; Vale W
J Biol Chem; 2004 Jul; 279(27):28036-44. PubMed ID: 15123686
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas.
Alexander JM; Bikkal HA; Zervas NT; Laws ER; Klibanski A
J Clin Endocrinol Metab; 1996 Feb; 81(2):783-90. PubMed ID: 8636304
[TBL] [Abstract][Full Text] [Related]
17. Identification of a functional binding site for activin on the type I receptor ALK4.
Harrison CA; Gray PC; Koerber SC; Fischer W; Vale W
J Biol Chem; 2003 Jun; 278(23):21129-35. PubMed ID: 12665502
[TBL] [Abstract][Full Text] [Related]
18. Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells.
Rejon CA; Hancock MA; Li YN; Thompson TB; Hébert TE; Bernard DJ
Cell Signal; 2013 Dec; 25(12):2717-26. PubMed ID: 24018044
[TBL] [Abstract][Full Text] [Related]
19. Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions.
Thompson TB; Woodruff TK; Jardetzky TS
EMBO J; 2003 Apr; 22(7):1555-66. PubMed ID: 12660162
[TBL] [Abstract][Full Text] [Related]
20. R-Smad competition controls activin receptor output in Drosophila.
Peterson AJ; Jensen PA; Shimell M; Stefancsik R; Wijayatonge R; Herder R; Raftery LA; O'Connor MB
PLoS One; 2012; 7(5):e36548. PubMed ID: 22563507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
